The Babak Lab shared a post on LinkedIn:
“Clinical Mondays: Pembrolizumab — Now in Subcutaneous Form
The FDA has approved pembrolizumab plus berahyaluronidase alfa-pmph (Keytruda Qlex) for subcutaneous (SC) injection in adults and adolescents (12+) across most solid tumor indications already approved for IV pembrolizumab.
Study Focus
Evaluate whether a subcutaneous formulation of pembrolizumab can match IV administration in pharmacokinetics, efficacy, and safety — while improving patient convenience.
Key Insights
• SC dosing achieved drug exposure comparable to IV infusion
• Similar efficacy observed in metastatic NSCLC: ORR 45% (SC) vs. 42% (IV)
• Administration time reduced from ~30 minutes to just minutes
• Greater flexibility for patients with limited venous access
Conclusion
Keytruda Qlex delivers pembrolizumab in a more convenient form — same efficacy, faster administration, and easier access for patients.”
More posts featuring Maria Babak on OncoDaily.